. Author manuscript; available in PMC: 2021 Aug 21.

Published in final edited form as: Nanoscale. 2020 Jun 17;12(31):16451–16461. doi: 10.1039/d0nr03226c

Table. 1.

IC₅₀ of ANS–TAT–AuNPs and 6-MP–TAT–AuNPs after 24 h incubation and DRI of MCF-7/ADR cells.

Samples	IC₅₀/μM ^*			DRI (W/O VRP)^*	DRI (W VRP)^*
Samples	MCF-7	MCF-7/ADR	MCF-7/ADR (W VRP)^*	DRI (W/O VRP)^*	DRI (W VRP)^*

ANS–TAT–AuNPs_4.1nm	9.0 ± 0.7	45.7 ± 3.5	19.5 ± 4.7	5.1	2.2
6-MP–TAT–AuNPs_4.1nm	7.4 ± 2.3	44.4 ± 6.5	20.2 ± 1.6	6.0	2.7
ANS–TAT–AuNPs_5.4nm	10.3 ± 1.2	25.2 ± 3.2	25.9 ± 4.2	2.4	2.5
6-MP–TAT–AuNPs_5.4nm	11.2 ± 1.5	20.5 ± 0.2	20.1 ± 2.2	1.8	1.8

calculated based on the concentration of ANS or 6-MP. W VRP: pre-treated with verapamil at 10 μM for 1 h; W/O VRP: without verapamil pre-treatment.